Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iC9-CAR19 Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia
NCT03016377Phase 1Active, not recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Mar 2012
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of IC9-CAR19 in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Number of participants with adverse events at 4 weeks. Started Mar 2012; status: active, not recruiting.
02
Drugs
IC9-CAR19
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03016377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03016377.